 |
English
|
正體中文
|
简体中文
|
全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2541314
線上人數 : 186
|
|
|
資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://libir.tmu.edu.tw/handle/987654321/65450
|
| 題名: | Chemotherapy Immunophenoprofiles in Non–small-cell Lung Cancer by Personalized Membrane Proteomics |
| 作者: | 韓嘉莉
Denise Utami Putri, Po-Hao Feng, Yuu-Hueih Hsu, Kang-Yun Lee, Feng-Wen Jiang, Lu-Wei Kuo, Yu-Ju Chen, Chia-Li Han |
| 貢獻者: | 臨床藥物基因體學暨蛋白質體學碩士學位學程 |
| 關鍵詞: | Keywords: non-small-cell lung cancer;peripheral blood mononuclear cells;personalized membrane proteomics |
| 日期: | 2018-03 |
| 上傳時間: | 2025-04-02 14:10:43 (UTC+8) |
| 摘要: | Abstract
Objectives: No study has addressed how the immune status at the molecular level is affected by first-line pemetrexed and cisplatin (PEM-CIS) combination therapy in patients with non-small-cell lung cancer (NSCLC). Thus, we aimed to identify the immune status from membrane proteome alterations in patients with NSCLC upon PEM-CIS treatment.
Methods: The paired peripheral blood mononuclear cells (PBMCs) were collected from four patients with lung adenocarcinoma before and after the first regimen of PEM-CIS treatment and applied quantitative membrane proteomics analysis.
Result: In the personalized PBMC membrane proteome profiles, 2424 proteins were identified as displaying patient-specific responsive patterns. We discovered an elevated neutrophil activity and a more suppressive T-cell phenotype with the downregulation of cytotoxic T lymphocyte antigen 4 degradation and the upregulation of type 2 T-helper and T-regulatory cells in the patient with the highest progression-free survival (PFS) of 14.5 months. Patients with a PFS of 2 months showed higher expressions of T-cell subsets, MHC class II pathways, and T-cell receptor signaling, which indicated an activated immune status.
Conclusion and clinical relevance: Without the additional isolation of specific immune cell populations, our study demonstrated that PEM-CIS chemotherapy altered patients' immune system in terms of neutrophils, T cells, and antigen presentation pathways. |
| 關聯: | Proteomics Clin Appl. 2018 Mar; 12(2) |
| 描述: | 【109-2 升等】臺北醫學大學教師升等專門著作
職別：專任
送審等級：副教授
著作送審 |
| 附註: | Erratum in
Chemotherapy Immunophenoprofiles in Non-Small-Cell Lung Cancer by Personalized Membrane Proteomics.
Utami Putri D, Feng PH, Hsu YH, Lee KY, Jiang FW, Kuo LW, Chen YJ, Han CL.
Proteomics Clin Appl. 2020 Mar;14(2):e1970064. doi: 10.1002/prca.201970064. Epub 2020 Jan 24. |
| 資料類型: | article |
| 顯示於類別: | [教師升等送審著作] 109
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 3 | 檢視/開啟 |
|
在TMUIR中所有的資料項目都受到原著作權保護.
|
